Medical/Pharmaceuticals
EpiVax and CUBRC Awarded FDA Contract Worth $2M for Development of Control Peptides for Immunogenicity Risk Assessment Assays Supporting Regulatory Filings of Generic Peptide Drugs
PROVIDENCE, R.I., Oct. 24, 2024 /PRNewswire/ -- EpiVax, Inc. ("EpiVax") and CUBRC, Inc. ("CUBRC") announce today that they have been awarded a two-year,$2 million contract (#75F40124C00094) from the Office of Generic Drugs (OGD) of the Food and Drug Administration (FDA) to develop standardized co...
2024-10-24 21:05
2395
Besmile Announces RMB 1 Million Donation to Support Shanghai 9th People's Hospital's Dental Service Development
SHANGHAI, Oct. 24, 2024 /PRNewswire/ -- Dental service provider Besmile proudly announces a donation ofRMB 1 million to Shanghai 9th People's Hospital, reinforcing its commitment to enhancing dental service capabilities within the industry. The fund will help elevate the medical facilities to cre...
2024-10-24 20:20
5662
Medera Announces Completion of Cohort A and Initiation of Dosing in Cohort B of MUSIC-HFpEF, a Phase 1/2a Clinical Trial Evaluating First-In-Human Gene Therapy SRD-002 for Heart Failure with Preserved Ejection Fraction
* Heart failure is a global pandemic with an estimated 64.3 million cases worldwide, costing overUS$100B per year * Heart failure with preserved ejection fraction (HFpEF) accounts for nearly half of all heart failure cases, but has limited disease-modifying therapeutics * Promising efficacy ...
2024-10-24 20:00
1783
SeekIn Presents Cost-Effective Two-Step Multi-Cancer Screening Strategy and Breakthrough Lung Cancer Early Detection Test at Early Detection of Cancer Conference in San Francisco
SAN DIEGO, Oct. 24, 2024 /PRNewswire/ -- SeekIn Inc, a leader in blood-based cancer early detection and monitoring technology, announced today its innovative two-step multi-cancer screening strategy at the Early Detection of Cancer Conference in San Francisco. This approach is designed to signifi...
2024-10-24 20:00
1360
Global Biopharma Thought Leaders Gather in London: Join the 2024 GenScript Biotech Global Forum for Cutting-Edge Insights
PISCATAWAY, N.J., Oct. 24, 2024 /PRNewswire/ -- Cell therapy, gene therapy, and mRNA vaccines are revolutionizing healthcare, offering innovative treatments for a wide range of diseases. However, as these therapies progress, they encounter challenges like safety assessments, cost control, and te...
2024-10-24 17:53
1683
The 2024 Seminar on International Communication of Chinese Medicine and Yi Medicine Big Health Industry Development Promotion Conference Held in Chuxiong, Yunnan Province
CHUXIONG, China, Oct. 24, 2024 /PRNewswire/ -- The 2024 Seminar on International Communication of Chinese Medicine and Yi Medicine Big Health Industry Development Promotion Conference was held in Chuxiong,Yunnan Province onOctober 21. The event was co-sponsored by the China Association of Chinese...
2024-10-24 15:48
5287
Pierre Fabre announce 1st Patient Dosed in Phase I/II of PFL-002/VERT-002, a targeted therapy in NSCLC with MET Alterations
Pierre Fabre Laboratories Announce First Patient Dosed in Phase I/II Clinical Trial of PFL-002/VERT-002, an Innovative Targeted Therapy Intended to Treat Non-Small Cell Lung Cancer with MET Alterations PFL-002/VERT-002 is a monoclonal antibody with a novel and differentiated mechanism of action,...
2024-10-24 15:15
2627
Founder of Hua Medicine Dr. Li CHEN was awarded the "C.C. Tan Life Science Industrialization Award"
SHANGHAI, Oct. 24, 2024 /PRNewswire/ -- The 17th "C.C. Tan Life Science Award" ceremony was held inShenyang, China, on October 9th. Dr. Li CHEN, Founder and Chief Executive Officer of Hua Medicine, was awarded the "C.C. Tan Life Science Industrialization Award". C.C. Tan Life Science Award has th...
2024-10-24 13:16
5183
J INTS BIO Presents Interim Findings from Phase 1/2 Clinical Trial of 4th-Generation EGFR-TKI 'JIN-A02' in NSCLC: A Potential Breakthrough in Overcoming Acquired Resistance to Targeted Therapy
SEOUL, South Korea, Oct. 24, 2024 /PRNewswire/ -- J INTS BIO, a pioneering biopharmaceutical company, has unveiled promising interim results from the Phase 1/2 clinical trial of its novel 4th-generation EGFR Tyrosine Kinase Inhibitor (TKI), JIN-A02, aimed at EGFR-mutated non-small cell lung cance...
2024-10-24 12:42
1975
J INTS BIO Presents Interim Results from the Preclinical Study of 'JIN-001' in Refractory Ovarian Cancer: A Promising Solution for Overcoming Drug Resistance
SEOUL, South Korea, Oct. 23, 2024 /PRNewswire/ -- J INTS BIO, a leader in oncology drug development, has revealed interim preclinical results of its second-generation synthetic HSP90 inhibitor, JIN-001, at the ENA (EORTC-NCI-AACR) Symposium held inBarcelona, Spain, from October 23-25, 2024. The ...
2024-10-24 10:45
1937
Hope Medicine Inc. Announces Positive Results from a Global Phase 2 Study of a First-in-Class Endometriosis Treatment and Breakthrough Therapy Designation
HMI-115 has demonstrated statistically significant improvement in endometriosis pain The mean dysmenorrhea pain score was reduced by 42% The mean non-menstrual pelvic pain score was reduced by 50% Most of the patients reported normal menstrual periods No typical peri-menopausal symptoms were re...
2024-10-24 08:08
4824
FDA Accepts New Drug Application and Grants Priority Review for TLX101-CDx (Pixclara®) Brain Cancer Imaging Agent
MELBOURNE, Australia, Oct. 24, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces thatthe United States (U.S.) Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for TLX101-CDx (Pixclara®[1]), an agent for the imaging of g...
2024-10-24 06:02
2216
Caliway Completed CBL-514 Phase 2b Study (CBL-0205) for Subcutaneous Fat Reduction
* The first and only lipolytic injectable for large area – CBL-514's last Phase2b study has been completed * Both CBL-514 Phase 2b studies used efficacy assessment tools, AFRS and MRI, in accordance with the U.S. FDA recommendation * CBL-514 Pivotal Phase 3 study is expected to initiate subj...
2024-10-24 01:42
2561
CorDx Selects MasterControl to Streamline Life Science Quality and Manufacturing Processes Globally
IVD leader adopts MasterControl Qx and Mx platforms to ensure regulatory compliance acrossChina, the US and more. SINGAPORE, Oct. 23, 2024 /PRNewswire/ -- MasterControl announced today that CorDx Inc., the global diagnostics company and leader in IVD research and development, has chosen MasterCo...
2024-10-23 23:17
2521
Lunit AI Predicts Breast Cancer Risk Up to 6 Years in Advance
* Two new studies show Lunit INSIGHT MMG cuts radiologist workload by 50% in a double reading environment while maintaining or improving screening quality, and predicts cancer risk up to six years in advance SEOUL, South Korea, Oct. 23, 2024 /PRNewswire/ -- Amid rising demands and a global shor...
2024-10-23 21:00
2832
SK bioscience Announces Approval of Its Quadrivalent Influenza Vaccine in Indonesia
* This approval paves the way for exports to the world's fourth most populous country. * SK bioscience aims to continue to grow as a global vaccine brand beyond Korea by leveraging the advantages of cell-cultured vaccines. SEONGNAM, South Korea, Oct. 23, 2024 /PRNewswire/ -- SK bioscience, a ...
2024-10-23 20:00
2977
Doceree forms Strategic Partnership with The Ward Marketing Group to Strengthen Its Global Footprint; Expands into Australian Market
Expanding its reach from 22 markets to include Australia, Doceree partners with The Ward Marketing Group to enhance HCP-patient engagement in the region through innovative marketing solutions. SYDNEY, Oct. 23, 2024 /PRNewswire/ -- Doceree, the world's first global network of physician-only platf...
2024-10-23 19:05
2020
CCTV+: Explore the Wizard of Oz in Jiangzhong Pharmaceutical Valley
BEIJING, Oct. 23, 2024 /PRNewswire/ -- This is a report from CCTV+: Want to cool down in the hot summer? Better to explore the Wizard of Oz in Jiangzhong Pharmaceutical Valley. In this wonderful green garden, you can meet muntjacs and birds. The ancient legend of Shennong tasted herbs is also u...
2024-10-23 15:38
4016
SK bioscience Announces Approval of Its Quadrivalent Influenza Vaccine in Indonesia
* This approval paves the way for exports to the world's fourth most populous
country.
* SK bioscience aims to continue to grow as a global vaccine brand beyond
Korea. SEONGNAM, South Korea, Oct. 23, 2024 /PRNewswire/ -- SK bioscience
2024-10-23 15:11
2671
Samsung Biologics reports third quarter 2024 financial results
* Recorded Q3'24 consolidated revenue of KRW 1.2 trillion * Recorded Q3'24 consolidated operating profit of KRW 338.6 billion * Continued business expansion through strong competitive edge in speed and execution INCHEON, South Korea, Oct. 23, 2024 /PRNewswire/ -- Samsung Biologics (KRX: 2079...
2024-10-23 14:55
1942
Week's Top Stories
Most Reposted
Wonder Raises USD 12 Million Venture Debt from HSBC Innovation Banking to Drive Growth and Expansion
[Picked up by 322 media titles]
2026-02-02 10:00
Agoda Launches Agoda Impact Lab at ASEAN Tourism Forum
[Picked up by 322 media titles]
2026-01-29 15:06
AI adoption is widespread, but developer confidence is still catching up, Agoda report finds
[Picked up by 312 media titles]
2026-02-03 11:00
Colebrook Bosson Saunders Officially Launches Lana, A Circular Ergonomic Laptop Stand for the Hybrid Generation
[Picked up by 303 media titles]
2026-02-03 12:00
Singapore Airshow 2026 Milestone Edition: 20 Years of Shaping the Aerospace Landscape as Asia-Pacific Drives Global Growth
[Picked up by 286 media titles]
2026-02-01 19:35